LogoCrystal's Coder Hub

H34.8112

23 min read

🧬 ICD-10 CM H34.8112 — Central Retinal Vein Occlusion, Right Eye, With Retinal Neovascularization

Billable Code Confirmed

ICD-10 CM H34.8112 is a fully billable, 7-character ICD-10-CM code valid for FY2026 facility and professional fee claims. The H34 category anchors the diagnosis to retinal vascular occlusions; the “8” subcategory designates other retinal vascular occlusions — which by ICD-10-CM convention captures venous events, as arterial occlusions are addressed in H34.0–H34.2. The 6th character “1” specifies the right eye, and the 7th character “2” designates retinal neovascularization as the documented complication, distinguishing this code from the NOS and macular edema variants within the same subcategory. All seven characters are required for claim submission; truncation to the non-billable parent H34.811 will result in claim rejection.

Non-Billable Parent Codes

H34.8 (Other retinal vascular occlusions) is a non-billable subcategory header lacking specificity for occlusion type, laterality, and complication —> it cannot be submitted as a standalone diagnosis code. H34.81 (Central retinal vein occlusion) adds occlusion type but still lacks laterality and complication detail, making it non-billable and subject to payer rejection under HIPAA code set standards. H34.811 (Central retinal vein occlusion, right eye) establishes laterality but remains a non-billable parent until the 7th character specifying the complication status is appended.

Clinical Context

The 7th character “2” in H34.8112 captures retinal neovascularization — a pathological proliferation of new, structurally fragile blood vessels on the retinal surface driven by hypoxia-induced overexpression of VEGF following central venous obstruction. This distinction is clinically critical because retinal neovascularization is the hallmark of ischemic (non-perfused) CRVO, the more severe subtype, and directly informs treatment with intravitreal anti-VEGF pharmacotherapy and panretinal photocoagulation (67228). Accurate use of H34.8112 versus H34.8110 (without neovascularization) or H34.8111 (with macular edema) requires explicit provider documentation naming neovascularization as the active complication — a CDI query is appropriate if the documentation describes “ischemic CRVO” without specifying the downstream complication. When neovascularization has extended anteriorly to the iris, query the provider for concurrent neovascular glaucoma documentation, which is coded separately and may qualify as a CC or MCC.

Code Classification

ICD-10 CM H34.8112 is a diagnosis code in ICD-10-CM Chapter 7 (Diseases of the Eye and Adnexa) and represents a retinal vascular condition — it is not a procedure code. Associated inpatient interventions such as intravitreal anti-VEGF injection (67028) or panretinal photocoagulation must be captured with separate CPT codes (for professional fee) or ICD-10-PCS codes (for inpatient facility). This code describes the diagnosis of central retinal vein occlusion with retinal neovascularization in the right eye, not the therapeutic response to it.

🔍 Code Description

Central retinal vein occlusion (CRVO) occurs when the primary venous drainage of the retina — the central retinal vein — is partially or completely obstructed, typically at the level of the lamina cribrosa where the vein exits the optic nerve head alongside the central retinal artery. The resultant venous hypertension causes increased hydrostatic pressure in the retinal capillaries, breakdown of the blood-retinal barrier, diffuse intraretinal hemorrhage, disc edema, and retinal ischemia proportional to the extent of capillary non-perfusion. In the ischemic subtype, extensive capillary dropout leads to tissue hypoxia, which stimulates overproduction of vascular endothelial growth factor (VEGF) — the molecular driver of the pathological retinal neovascularization captured by H34.8112. Unlike the non-ischemic (perfused) subtype, which more commonly presents with macular edema as the primary complication (coded as H34.8111), ischemic CRVO carries substantial risk of irreversible vision loss and neovascular sequelae if untreated, justifying hospital-level evaluation and management.1,2

Retinal neovascularization in the context of H34.8112 represents a time-sensitive ophthalmic emergency: the new vessels are structurally incompetent, prone to spontaneous hemorrhage into the vitreous (H43.11), and may proliferate anteriorly onto the iris (rubeosis iridis) and into the anterior chamber angle — precipitating neovascular glaucoma, which is coded separately using H40.510 (or the appropriate stage-specific variant) and may serve as a CC or MCC in the DRG grouper. Inpatient admissions coded with H34.8112 typically involve acute management of ischemic CRVO sequelae, including intravitreal anti-VEGF injection (67028), panretinal photocoagulation (67228), or pars plana vitrectomy when vitreous hemorrhage has occurred. Accurate 7th character assignment is essential not only for billing integrity but for reflecting clinical complexity in the medical record and supporting CDI-driven DRG optimization within MDC 02.3,6

🌳 Code Tree / Hierarchy

H34 Retinal vascular occlusions ❌ Non-billable
│
├── H34.0 Transient retinal artery occlusion ❌ Non-billable
│   ├── H34.00 ...unspecified eye ✅ Billable
│   ├── H34.01 ...right eye ✅ Billable
│   └── H34.02 ...left eye ✅ Billable
│
├── H34.1 Central retinal artery occlusion ❌ Non-billable
│   ├── H34.10 ...unspecified eye ✅ Billable
│   ├── H34.11 ...right eye ✅ Billable
│   └── H34.12 ...left eye ✅ Billable
│
└── H34.8 Other retinal vascular occlusions ❌ Non-billable
│
├── H34.81 Central retinal vein occlusion ❌ Non-billable
│   ├── H34.811 ...right eye ❌ Non-billable
│   │   ├── H34.8110 ...not otherwise specified ✅ Billable
│   │   ├── H34.8111 ...with macular edema ✅ Billable
│   │   └── H34.8112 ...with retinal neovascularization ◀ THIS CODE ✅ Billable
│   ├── H34.812 ...left eye ❌ Non-billable
│   │   ├── H34.8120 ...not otherwise specified ✅ Billable
│   │   ├── H34.8121 ...with macular edema ✅ Billable
│   │   └── H34.8122 ...with retinal neovascularization ✅ Billable
│   └── H34.819 ...unspecified eye ❌ Non-billable
│       ├── H34.8190 ...not otherwise specified ✅ Billable
│       ├── H34.8191 ...with macular edema ✅ Billable
│       └── H34.8192 ...with retinal neovascularization ✅ Billable
│
├── H34.82 Venous engorgement (incipient CRVO) ❌ Non-billable
└── H34.83 Tributary (segmental) retinal vein occlusion ❌ Non-billable

Neovascularization vs. Macular Edema — Why the 7th Character Controls Reimbursement and Auth

H34.8112 (retinal neovascularization) signals ischemic CRVO and directly supports medical necessity for panretinal photocoagulation and serial intravitreal anti-VEGF therapy; payers including Medicare and commercial MAOs scrutinize prior auth requests for these high-cost interventions and require the precise 7th character to avoid denials — using the less-specific H34.8110 in place of H34.8112 when neovascularization is documented constitutes undercoding and may constitute a compliance exposure.

Tip

If the ophthalmologist documents both macular edema AND retinal neovascularization in the same right eye at the same encounter, the coder must select the 7th character reflecting the clinically dominant or primary complication — or issue a CDI query clarifying which complication drove the admission. ICD-10-CM does not support simultaneous assignment of H34.8111 and H34.8112 for the same eye-level encounter, as these represent mutually exclusive 7th character designations.

✅ Includes

  • Thrombosis of central retinal vein, right eye, with neovascularization — Thrombotic occlusion at the lamina cribrosa with documented downstream retinal neovascular response maps to H34.8112 when laterality and complication are explicitly stated by the provider.
  • Ischemic central retinal vein occlusion, right eye, with new vessel formation — Provider documentation of ischemic CRVO with new vessel growth on the retinal surface, disc, or extending anteriorly from the retina is captured under this code.
  • Central retinal venous obstruction, right, with retinal angiogenesis — Alternate clinical phrasing for VEGF-mediated pathological vessel proliferation in the setting of CRVO maps here when the right eye and neovascularization are both explicitly documented.
  • CRVO, right eye, with rubeosis-stage retinal NV — When iris neovascularization (rubeosis) is present, the retinal NV that typically precedes it should be documented and coded; H34.8112 captures the retinal component while neovascular glaucoma requires a separate H40.5x code.
  • Retinal VEGF-driven vessel proliferation secondary to central venous occlusion, right eye — Pathological angiogenesis driven by CRVO-related hypoxia and overexpression, where the neovascularization is retinal in location, maps to this code when the right eye is specified.

❌ Excludes

Excludes 1

Danger

The most common Excludes 1 error for H34.8112 is simultaneous assignment of two 7th character variants of H34.811 for the same right eye at the same encounter — most often H34.8111 (macular dema) plus H34.8112 (neovascularization). The 7th character is a mutually exclusive designator: the coder must select the single documented complication or issue a provider query when documentation describes both; payers will deny or downcode claims where conflicting specificity codes are submitted for the same eye.

  • ICD-10 CM H34.8110 — Central retinal vein occlusion, right eye, not otherwise specified. This variant is mutually exclusive with H34.8112 for the same right eye at the same encounter; when neovascularization is explicitly documented, the fully specific 7th character code supersedes the NOS assignment, making simultaneous coding redundant and non-compliant.
  • ICD-10 CM H34.8111 — Central retinal vein occlusion, right eye, with macular edema. When documentation supports both macular edema and retinal neovascularization in the same eye at the same encounter, the coder must assign only the code reflecting the primary or dominant complication; simultaneous use of both 7th character variants for the same eye is not supported by ICD-10-CM conventions and should prompt a provider query.

Excludes 2

  • H35.00 — Unspecified background retinopathy. If hypertensive or diabetic background retinopathy is separately and explicitly documented as a co-existing finding distinct from the CRVO, it may be coded in addition to H34.8112 as a secondary diagnosis, since these represent clinically distinct retinal pathologies that can coexist.
  • H40.510 — Glaucoma secondary to other eye disorders, right eye, stage unspecified. Neovascular glaucoma developing as a downstream complication of CRVO-related iris neovascularization is a separately codeable condition that must be coded with its own H40.5x_ code when documented; it may additionally qualify as a CC or MCC and should never be omitted from the secondary diagnosis list.

📋 Clinical Overview

Ischemic vs. Non-Ischemic CRVO — Complication Spectrum and Code Selection

Central retinal vein occlusion is clinically stratified into ischemic (non-perfused) and non-ischemic (perfused) subtypes based on fluorescein angiography capillary perfusion assessment and the presence of relative afferent pupillary defect. The ICD-10-CM 7th character structure of H34.81x codes mirrors this clinical spectrum: the neovascularization variant (H34.8112) is the signature complication of ischemic CRVO, while the macular edema variant (H34.8111) spans both subtypes. Code selection therefore requires documentation of the specific complication — not merely the subtype designation — to be technically accurate under ICD-10-CM conventions.2,4

FeatureH34.8112H34.8111H34.8110
Documented ComplicationRetinal neovascularizationMacular edemaNone/not specified
CRVO SubtypeIschemic (non-perfused)Ischemic or non-ischemicUnspecified/early
VEGF DriveHigh — fuels neovascular proliferationModerate — drives edema fluid accumulationLow to undetermined
Risk of NV GlaucomaHigh — iris NV (rubeosis) commonModerateLow
Primary TreatmentAnti-VEGF (intravitreal) + panretinal photocoagulation (67228); possible vitrectomyAnti-VEGF (67028) or dexamethasone implant (67027)Observation vs. treatment based on ischemic conversion
Hospitalization DriverAcute neovascular emergency, surgical interventionAnti-VEGF administration, ischemic monitoringDiagnostic workup, close outpatient observation
DRG ImpactMost complex — highest likelihood of CC/MCC from downstream complicationsModerateLowest complexity within family

Important

CDI trigger: If the retinal specialist’s note documents “rubeosis iridis,” “iris neovascularization,” or “neovascular glaucoma” in a right eye CRVO encounter, this is a high-probability indicator that retinal neovascularization is also present — query to confirm H34.8112 is appropriate and whether H40.510 (neovascular glaucoma) should also be assigned. These two codes together can produce a CC/MCC capture that shifts DRG assignment from 126 to 125 or 124.

Manifestations & Symptom Burden

  • Sudden, painless monocular vision loss (right eye) — The acute presenting event; severity correlates with the degree of macular ischemia, foveal capillary drop-out, and central scotoma extent.
  • Diffuse “blood and thunder” retinal hemorrhages — Flame-shaped and blot hemorrhages in all four retinal quadrants from venous engorgement are characteristic on fundoscopy; hemorrhage density correlates with occlusion completeness.
  • Dilated, tortuous retinal veins — Pathognomonic venous engorgement throughout the retinal vasculature reflects elevated intraluminal venous pressure from the central obstruction and is present in all CRVO variants.
  • Optic disc edema — Present in the acute phase as a marker of retrograde pressure on the optic nerve head; resolves over weeks to months as the obstruction evolves.
  • Retinal neovascularization — The specific complication captured by H34.8112; abnormal new vessel proliferation on the retinal surface or disc appears weeks to months post-occlusion in ischemic cases and is VEGF-driven.
  • Vitreous hemorrhage — A late, sight-threatening complication from rupture of fragile neovascular membranes; when documented by the provider, code separately as H43.11 (vitreous hemorrhage, right eye), which may serve as a CC or MCC driver in DRG assignment.

Tip

Manifestation coding note: Retinal neovascularization is NOT coded separately with its own standalone ICD-10-CM code when it is directly attributable to CRVO — the 7th character “2” in H34.8112 already captures it as an integral complication. However, downstream complications including vitreous hemorrhage (H43.11), neovascular glaucoma (H40.510), and tractionretinal detachment (H33.41) are distinctly separate conditions that require their own codes when explicitly documented and must never be omitted as potential CC/MCC contributors.

💰 HCC Risk Adjustment

HCC ModelHCC CategoryHCC LabelRAF Contribution
CMS HCC v28N/ANot Mapped0.000
CMS HCC v24 (legacy)N/ANot Mapped0.000
Encounter/RAPSN/ANo RAF creditN/A

ICD-10 CMH34.8112 does not generate any direct RAF score contribution under CMS HCC v28 or its predecessor v24, as retinal vein occlusion is not recognized as an independent risk-bearing condition in the current risk adjustment model. The code’s clinical importance for inpatient facility coding lies in DRG complexity capture rather than risk scoring. Coders and CDI specialists working on Medicare Advantage or ACO risk adjustment cases should instead focus on ensuring full annual capture of the systemic comorbidities that predispose to CRVO: diabetes mellitus with ophthalmic complications (e.g., E11.319 → HCC 19 under v28), essential hypertension (I10 — note: not HCC mapped independently but frequently accompanies HCC-mapped cardiovascular conditions), and hypercoagulable states. MEAT documentation standards must be satisfied for each HCC-mapped condition to be valid for risk adjustment submission; CDI teams should confirm provider attestation is current and complete at every eligible encounter. The absence of HCC mapping for H34.8112 does not diminish its critical role in supporting medical necessity for high-cost ophthalmic interventions such as serial intravitreal anti-VEGF injections.5

🏥 MS-DRG Assignment

ScenarioDRGDRG TitleRel. Wt. (FY2026 est.)GMLOS (est.)
With MCC124Other Disorders of the Eye with MCC~0.9200~2.5 days
With CC125Other Disorders of the Eye with CC~0.7100~2.0 days
Without CC/MCC126Other Disorders of the Eye without CC/MCC~0.5500~1.5 days

ICD-10 CMH34.8112 as the principal diagnosis sequences to MDC 02 (Diseases and Disorders of the Eye) and groups to the DRG 124/125/126 family under the MS-DRG v43 grouper. The base case, DRG 126, carries a low relative weight and short GMLOS, making CC/MCC capture essential for financial performance on complex ischemic CRVO admissions. Neovascular glaucoma (H40.510) is a frequent and clinically appropriate secondary code in the CRVO neovascular setting and may qualify as a CC or MCC depending on staging and grouper version — this should be a priority CDI target in every H34.8112 hospitalization. If the attending documents and a qualifying OR procedure is performed — most commonly pars plana vitrectomy for vitreous hemorrhage — the grouper will assign a surgical DRG within MDC 02, which typically carries a significantly higher relative weight; coders must confirm that the procedure occurred in the OR suite and that the PCS code is correctly classified to capture this. Systemic comorbidities such as poorly controlled hypertension (I10) or diabetes mellitus (E11.xx) should always be coded as secondary diagnoses to reflect accurate clinical complexity, even when they do not independently shift DRG. CDI review of the ophthalmology operative and consult notes at time of admission — not only at discharge — is strongly recommended to prevent missed CC/MCC opportunities in ischemic CRVO cases.3,5

🔗 Related ICD-10-CM Codes

Central Retinal Vein Occlusion Family

  • H34.8110 — Central retinal vein occlusion, right eye, not otherwise specified; use when provider documents CRVO but does not specify a complication.
  • H34.8111 — Central retinal vein occlusion, right eye, with macular edema; the non-ischemic CRVO workhorse code for anti-VEGF and steroid implant management.
  • H34.8122 — Central retinal vein occlusion, left eye, with retinal neovascularization; the contralateral equivalent of H34.8112.
  • H34.8192 — Central retinal vein occlusion, unspecified eye, with retinal neovascularization; avoid unless laterality is truly undocumentable after query.

Downstream Complications and Associated Codes

  • H43.11 — Vitreous hemorrhage, right eye; late complication from rupture of neovascular membranes and a critical CC/MCC target in ischemic CRVO.
  • H33.41 — Traction detachment of retina, right eye; severe late sequela of fibrovascular proliferation extending from retinal neovascularization.
  • H40.510 — Glaucoma secondary to other eye disorders, right eye, stage unspecified; the appropriate code for neovascular glaucoma secondary to CRVO; verify correct stage character based on provider documentation.
  • H34.11 — Central retinal artery occlusion, right eye; distinct arterial pathophysiology — sudden, painless, cherry red spot presentation versus venous pattern — do not conflate with CRVO.
  • I10 — Essential (primary) hypertension; the most prevalent systemic risk factor for CRVO and should routinely appear as a secondary diagnosis.

🛠️ Commonly Associated CPT Codes

  • 67028 — Intravitreal injection of pharmacologic agent (e.g., bevacizumab, ranibizumab, aflibercept). This is the primary procedural code for anti-VEGF pharmacotherapy in H34.8112 cases; serial injection courses are common in ischemic CRVO with neovascularization, and each session requires a separate claim with medical necessity documented via the H34.8112 diagnosis. NCCI does not bundle 67028 with diagnostic imaging performed at the same session when distinct services are rendered.
  • 67228 — Treatment of extensive or progressive retinopathy; photocoagulation (panretinal). PRP is standard of care for retinal neovascularization in ischemic CRVO to ablate ischemic retina and reduce VEGF stimulus; often performed in combination with intravitreal anti-VEGF. Modifier -RT must be appended for the right eye on professional fee claims.
  • 92235 — Fluorescein angiography with interpretation and report, unilateral or bilateral. FA is essential for confirming ischemic CRVO, quantifying capillary non-perfusion, and odentifying neovascularization on the disc or retina; required documentation for H34.8112 coding justification in many payer medical necessity reviews.
  • 92250 — Fundus photography with interpretation and report. Wide-field fundus imaging documents the extent of retinal hemorrhage, neovascularization location, and serial treatment response; supports medical record documentation for H34.8112 and may be billed separately from angiography when both are performed.
  • 67027 — Implantation of intravitreal drug delivery system (e.g., dexamethasone implant / Ozurdex). Used in CRVO-related macular edema management; if the provider opts for steroid implant rather than anti-VEGF in a neovascular CRVO case, 67027 is the appropriate procedural code — not 67028. Cannot be billed with 67028 at the same session in the same eye.
  • 67036 — Vitrectomy, mechanical, pars plana approach. Indicated when vitreous hemorrhage secondary to neovascular rupture prevents visual rehabilitation; when performed inpatient and classified as an OR procedure, this CPT shifts the DRG to a surgical assignment within MDC 02.

NCCI Bundling Considerations

NCCI bundles 92235 (fluorescein angiography) and 92250 (fundus photography) when performed by the same provider on the same date for the same eye, so coders should confirm that the clinical record supports distinct medical necessity for each service before billing both. Intravitreal injection (67028) is not bundled with office-level E/M services on the same date if a significant, separately identifiable E/M is performed, requiring modifier -25 on the E/M claim. Panretinal photocoagulation (67228) and intravitreal injection (67028) may both be reported on the same date if performed in separate sessions or if clearly documented as distinct procedures with separate medical necessity; review current NCCI edits and MAC guidance before billing both on the same date of service.

🔬 ICD-10-PCS Crosswalk

  • 3E0C3GC — Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach. This is the approximate PCS code for inpatient intravitreal anti-VEGF injection (bevacizumab, ranibizumab, or aflibercept) performed at the bedside or in a procedure room during a CRVO admission. Verify the correct substance qualifier character with your facility’s PCS codebook, as the qualifier may vary by agent (e.g., anti-neoplastic vs. other therapeutic substance).7
  • 085N3ZZ — Destruction of Retinal Vessel, Right, Percutaneous Approach. Approximate PCS code for panretinal photocoagulation (laser ablation of ischemic retina/neovascular tissue) in the right eye, performed via indirect laser delivery or **pars plana approac**h. Destruction is the correct root operation for photocoagulation because the intent is to ablate (destroy) pathological neovascular or ischemic retinal tissue.
  • 08D43ZZ — Extraction of Vitreous, Right, Percutaneous Approach. PCS code for pars plana vitrectomy (removal of hemorrhagic vitreous) in the right eye when performed as an inpatient OR procedure; Extraction is the correct root operation for mechanical vitrectomy as it involves pulling or stripping out the vitreous body. Confirm OR procedure status for DRG surgical assignment.7
  • 3E0C30Z — Introduction of Antineoplastic into Eye, Percutaneous Approach. Alternate PCS Administration code applicable when bevacizumab (Avastin) is classified under the antineoplastic substance qualifier at your facility; code assignment depends on the facility’s substance classification policy and should be confirmed with your PCS codebook and CDI guidance.

💊 Coding Scenarios and Examples

Scenario 1 — Ischemic CRVO with Retinal NV, Admitted for Intravitreal Anti-VEGF

A 67-year-old male with essential hypertension (I10) and hyperlipidemia is admitted following sudden painless vision loss in the right eye over the prior 24 hours. Fluorescein angiography confirms ischemic central retinal vein occlusion with diffuse capillary non-perfusion and retinal neovascularization on the disc and periphery. The retinal surgeon performs intravitreal bevacizumab injection in the right eye. The admission note documents I10 as an underlying contributing factor.

Sequencing explanation: H34.8112 is the principal diagnosis because CRVO with neovascularization is the condition chiefly responsible for the admission after study. I10 is coded as a secondary diagnosis per ICD-10-CM guidelines — it is a predisposing systemic condition, not the primary reason for admission. Without a qualifying MCC, this case groups to DRG 126; hypertension alone is typically not a CC/MCC driver in the eye MDC. CDI note: Query the provider for documentation of disc neovascularization vs. retinal neovascularization specifically, as the location may affect anti-VEGF dosing documentation and supports H34.8112 over H34.8110.

Scenario 2 — CRVO Right Eye with NV Plus Neovascular Glaucoma (CC/MCC Capture)

A 72-year-old female with a three-week history of right eye vision loss is admitted. Exam reveals ischemic CRVO, right eye, with retinal neovascularization and rubeosis iridis. IOP in the right eye is 38 mmHg; the attending documents neovascular glaucoma secondary to CRVO. Intravitreal ranibizumab is administered, and topical and systemic IOP-lowering agents are initiated.

Sequencing explanation: H34.8112 drives PDX as the CRVO is the root cause of the admission. H40.510 (neovascular glaucoma, right eye, stage unspecified) is coded as a secondary diagnosis and may qualify as a CC depending on your facility’s MS-DRG grouper version — verify against the CC/MCC Exclusion List in FY2026 DRG tables, as H34.8112 and H40.510 must not be on each other’s exclusion list for CC credit to apply. If H40.510 qualifies as a CC, this case shifts from DRG 126 to DRG 125, improving relative weight and reimbursement. CDI note: Document the stage of neovascular glaucoma explicitly — stage 1 through 4 — as this affects the precision of H40.51x code assignment and could influence clinical coding defensibility on audit.

Scenario 3 — CRVO with Vitreous Hemorrhage Requiring Pars Plana Vitrectomy

A 70-year-old male with previously diagnosed ischemic CRVO (right eye) is admitted urgently with sudden complete vision loss in the right eye. Exam confirms dense vitreous hemorrhage from ruptured retinal neovascular membranes. The ophthalmologist performs pars plana vitrectomy (PPV) in the OR. Pathology confirms hemorrhagic vitreous with fibrovascular proliferation consistent with CRVO-associated neovascularization.

  • Principal Dx: H34.8112
  • Secondary Dx: H43.11
  • Procedure (CPT): 67036-RT
  • Procedure (PCS): 08D43ZZ

Sequencing explanation: H34.8112 remains the appropriate PDX as the CRVO with neovascularization is the underlying condition driving the vitreous hemorrhage and the admission. H43.11 (vitreous hemorrhage, right eye) is coded as a secondary diagnosis and may qualify as a CC or MCC — confirm in the FY2026 CC/MCC table. Because 67036 is an OR procedure (pars plana vitrectomy), the grouper may override the DRG 124/125/126 medical family and assign a higher-weighted surgical DRG within MDC 02; confirm OR status and PCS code accuracy before final claim submission. CDI note: Ensure the operative note explicitly states “pars plana vitrectomy” and that the indication (vitreous hemorrhage secondary to CRVO-related neovascularization) is clearly documented to support both the principal diagnosis and the surgical DRG.

⚠️ Coding Pitfalls and Tips

  1. Truncating to the Non-Billable Parent H34.811 — The single most common error is submitting H34.811 (right eye, no complication specified) when the provider has clearly documented neovascularization. H34.811 is a non-billable parent and will be rejected on all payer types; always assign the full 7-character H34.8112 when neovascularization is documented. Review the discharge summary and retinal specialist note for the specific complication language before finalizing code assignment.

  2. Confusing Central Retinal VEIN Occlusion with Retinal ARTERY Occlusion — H34.8112 captures venous occlusion (H34.8 series), while central retinal ARTERY occlusion is coded under H34.11 (right eye); these are pathophysiologically and clinically distinct and are never interchangeable. Arterial occlusion presents with a cherry-red spot and profound acute vision loss from ischemic whitening of the inner retina, whereas venous occlusion produces the diffuse hemorrhagic “blood and thunder” fundus. Confirm the vascular type in the ophthalmologist’s documentation before code assignment.

  3. Missing Secondary Diagnoses That Drive CC/MCC and Risk Adjustment — Failing to code comorbid hypertension (I10), diabetes mellitus (E11.xx), or hypercoagulable states as secondary diagnoses leaves DRG complexity and risk score on the table. These systemic conditions are frequently documented in CRVO admissions and may also be queried if a vascular workup is performed during the stay. Coders should review the H&P, labs, and medicine or hematology consultation notes for undercoded systemic conditions that meet the UHDDS secondary diagnosis definition.

  4. Omitting Neovascular Glaucoma as a Separate Diagnosis — Neovascular glaucoma is a distinct, separately codeable condition that develops downstream of CRVO-driven iris and angle neovascularization. It is NOT captured within H34.8112; if the provider documents elevated IOP, rubeosis iridis, or neovascular glaucoma, assign H40.510 (or the appropriate staged variant) as a secondary diagnosis. This code may qualify as a CC in the FY2026 MS-DRG grouper alongside H34.8112 as PDX — a CDI query should be standard practice when rubeosis is mentioned in ophthalmology notes.

  5. Incorrect PDX Selection When Surgery Drives the Admission — When a patient is admitted specifically for a scheduled surgical procedure (e.g., elective pars plana vitrectomy for vitreous hemorrhage), the UHDDS definition of principal diagnosis requires careful evaluation of what was “established after study to be chiefly responsible for the admission.” In some cases, H43.11 (vitreous hemorrhage) may be the more accurate PDX rather than H34.8112, depending on the clinical circumstances and attending documentation — do not default to the etiology code as PDX when the complication is the primary driver of hospitalization.

  6. Failing to Query When Documentation States Only “Ischemic CRVO” Without Specifying the Complication — Ischemic CRVO alone is not sufficient to assign H34.8112; the 7th character requires specific documentation of retinal neovascularization as the named complication. If the note says “ischemic CRVO” without listing neovascularization as a finding, the default is H34.8110 (NOS) unless a CDI query confirms neovascularization is present. Issuing a timely query — with the fluorescein angiography report as clinical context — is both compliant and appropriate under AHIMA/AAPC query standards.

📚 Sources

1. Centers for Medicare & Medicaid Services; National Center for Health Statistics. *ICD-10-CM Official Guidelines for Coding and Reporting, FY2026.* CMS; 2025. 2. American Academy of Ophthalmology. *Preferred Practice Pattern: Retinal Vein Occlusions.* AAO; 2019 (Updated 2022). 3. Centers for Medicare & Medicaid Services. *MS-DRG Definitions Manual, Version 43.* CMS; FY2026. 4. Hayreh SS, Zimmerman MB. Central retinal vein occlusion: natural history of visual outcome. *JAMA Ophthalmology.* 2012;130(5):535–544. 5. Centers for Medicare & Medicaid Services. *2024 Advance Notice Technical Specifications: CMS-HCC Risk Adjustment Model v28.* CMS; 2024. 6. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. *Progress in Retinal and Eye Research.* 2005;24(4):493–519. 7. American Hospital Association (AHA). *Coding Clinic for ICD-10-CM and ICD-10-PCS.* AHA; relevant quarterly issues 2023–2025. 8. AAPC. *ICD-10-CM Expert for Hospitals, 2026 Edition.* American Academy of Professional Coders; 2026.

Graph View

Recent Notes